Author

Camille Grandclément

Observed names: C. Grandclement, C. Grandclément, Camille GrandClément, Camille Grandclement, Camille GrandclÃ©ment

Institution: Ichnos Sciences (United States)

Observed institutions: Inserm, Aix-Marseille Université, Centre Hospitalier Universitaire de Besançon, Ludwig Cancer Research, Université Bourgogne Franche-Comté, Ichnos Sciences (United States), Établissement Français du Sang, Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique, Université de Franche-Comté, University of Lausanne

ORCID: 0009-0005-3545-8243

Observed ORCID: 0009-0005-3545-8243

OpenAlex ID: A5042256248

Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis

2017 · Sara Trabanelli, Mathieu F. Chevalier, et al. · Nature Communications · 237

PDF

Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells

2016 · Godehard Scholz, Camilla Jandus, et al. · EBioMedicine · 121

PDF

Novel Role for STAT3 in Transcriptional Regulation of NK Immune Cell Targeting Receptor MICA on Cancer Cells

2011 · Romain Bedel, Antoine Thiery-Vuillemin, et al. · Cancer Research · 109

Neuropilins: A New Target for Cancer Therapy

2011 · Camille Grandclement, Christophe Borg · Cancers · 100

PDF

The Transcription Factor Tcf1 Contributes to Normal NK Cell Development and Function by Limiting the Expression of Granzymes

2017 · Beena Jeevan-Raj, Jasmine Gehrig, et al. · Cell Reports · 97

PDF

Neuropilin-2 Expression Promotes TGF-β1-Mediated Epithelial to Mesenchymal Transition in Colorectal Cancer Cells

2011 · Camille Grandclement, Jean René Pallandre, et al. · PLoS ONE · 96

PDF

Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance

2010 · Carole Henry, Marina Deschamps, et al. · Blood · 80

Adaptations of Natural Killer Cells to Self-MHC Class I

2014 · StÃ©phanie Bessoles, Camille GrandclÃ©ment, et al. · Frontiers in Immunology · 41

PDF

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma

2024 · C. Grandclément, C. Estoppey, et al. · Nature Communications · 23

PDF

Activation by SLAM Family Receptors Contributes to NK Cell Mediated “Missing-Self” Recognition

2016 · Elisenda Alari-Pahissa, Camille Grandclément, et al. · PLoS ONE · 13

PDF

NK Cells Respond to Haptens by the Activation of Calcium Permeable Plasma Membrane Channels

2016 · Camille Grandclément, Horst Pick, et al. · PLoS ONE · 10

PDF

Opposing Mcl-1, the GALIG proapoptotic gene is upregulated as neutrophils die and underexpressed in Acute Myeloid Leukemia cells

2013 · Lucile Mollet, Pauline Robinet, et al. · Molecular Immunology · 9

Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL

2022 · Sammicheli Stefano, Camille Grandclement, et al. · Blood · 8

ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma

2021 · Sammicheli Stefano, Camille Grandclement, et al. · Blood · 7

Inhibitory Receptor-Mediated Regulation of Natural Killer Cells

2014 · Elisenda Alari-Pahissa, Camille Grandclement, et al. · Critical Reviews in Immunology · 7

Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity

2025 · Jeremy Loyau, Thierry Monney, et al. · mAbs · 4

PDF

Neuropilin-2 and epithelial to mesenchymal transition in colorectal cancer cells.

2010 · C. Grandclement, R. Bedel, et al. · Journal of Clinical Oncology · 3

P871: Isb 1442, a First-in-class Cd38 and Cd47 Bispecific Antibody Innate Cell Modulator for the Treatment of Cd38 Positive Hematological Malignancies

2022 · C. Grandclement, C. Estoppey, et al. · HemaSphere · 1

Supplementary Data 1 from Novel Role for STAT3 in Transcriptional Regulation of NK Immune Cell Targeting Receptor MICA on Cancer Cells